In December Aspen announced the launch of Mounjaro (tirzepatide) in SA.
“This once-weekly injection is a new treatment option for adults with type 2 diabetes whose condition is not adequately controlled with current therapies. Mounjaro is a glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It mimics the effects of these natural hormones, which help regulate blood sugar levels.” - BusinessLive (20 Dec 2024) -
On 23 Dec2024 Business Day reported that Aspen has applied to the SA Health Products Regulatory Authority (SAHPR) to register tirzepatide a weight-loss medication.
“While doctors can currently prescribe tirzepatide ‘off-label’ for weight loss, official registration with SAHPRA would allow Aspen to market the drug for this purpose actively. This is significant given the rapid growth of the global weight-loss drug market, estimated to reach between $150bn and $180bn by 2030.”